- The CEO of Axovant, a biotech founded by 32-year-old Vivek Ramaswamy, has stepped down after the company’s lead Alzheimer’s drug failed.
- David Hung, along with the company’s chief operating officer, are leaving to pursue other opportunities, Axovant’s parent company Roivant Sciences said in a news release Monday.
- Hung joined Axovant just 10 months ago after his previous company Medivation sold to Pfizer for $US14 billion.
Axovant’s CEO David Hung, who joined the company 10 months ago, resigned Monday to “pursue other opportunities.” The company’s chief operating officer Marion McCourt resigned under similar circumstances, and three members left the board.
“We can’t justify it,” Hung told Business Insider in January after the drug failed a trial that looked at its use for dementia with Lewy bodies.
Axovant, which is one of a number companies under the Roivant Sciences umbrella, will continue on with veteran Roivant executive Dr. Pavan Cheruvu stepping in as CEO.
“Roivant remains firmly committed to Axovant’s long-term success. Axovant will need to operate as a lean, entrepreneurial organisation in the near term,” Ramaswamy, the chairman of Axovant, said in a news release. “n that context, Pavan is the right leader for the company at this time. Pavan is emblematic of the future industry leaders we hope to cultivate within Roivant, and I have full confidence in his ability to rebuild Axovant.”
Axovant’s stock fell by more than 20% on Monday morning.